Catalyst Pharmaceuticals (CPRX) Total Liabilities (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Total Liabilities of $134.9 million for Q1 2026, up 17.74% year-on-year from $114.6 million in Q1 2025, and down 9.88% on a QoQ basis from $149.7 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Total Liabilities data on file, last reported at $134.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 17.74% year-over-year to $134.9 million; the trailing twelve-month figure through Mar 2026 stood at $134.9 million (up 17.74% YoY), and the FY2025 full-year result was $149.7 million, up 20.95% from the prior year.
- Total Liabilities for Q1 2026 stood at $134.9 million, down from $149.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $149.7 million in Q4 2025 and bottomed at $26.2 million in Q2 2022.
- The 5-year median for Total Liabilities is $85.3 million (2024), against an average of $90.9 million.
- Peak annual rise in Total Liabilities reached 175.0% in 2023, while the deepest fall reached 2.52% in 2023.
- A 5-year view of Total Liabilities shows it stood at $75.2 million in 2022, then gained by 9.34% to $82.2 million in 2023, then surged by 50.52% to $123.8 million in 2024, then rose by 20.95% to $149.7 million in 2025, then dropped by 9.88% to $134.9 million in 2026.
- The last three Total Liabilities figures came in at $134.9 million (Q1 2026), $149.7 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 134.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.91 Mn |
| Dec 31, 2025 | 149.71 Mn |
| Sep 30, 2025 | 131.36 Mn |
| Jun 30, 2025 | 115.89 Mn |
| Mar 31, 2025 | 114.59 Mn |
| Dec 31, 2024 | 123.78 Mn |
| Sep 30, 2024 | 111.07 Mn |
| Jun 30, 2024 | 97.71 Mn |
| Mar 31, 2024 | 85.26 Mn |
| Dec 31, 2023 | 82.23 Mn |
| Sep 30, 2023 | 64.66 Mn |
| Jun 30, 2023 | 68.60 Mn |
| Mar 31, 2023 | 73.57 Mn |
| Dec 31, 2022 | 75.21 Mn |
| Sep 30, 2022 | 63.07 Mn |
| Jun 30, 2022 | 26.22 Mn |
| Mar 31, 2022 | 26.75 Mn |
| Dec 31, 2021 | 30.96 Mn |
| Sep 30, 2021 | 24.59 Mn |
| Jun 30, 2021 | 20.19 Mn |
| Mar 31, 2021 | 18.57 Mn |
| Dec 31, 2020 | 22.76 Mn |
| Sep 30, 2020 | 18.23 Mn |
| Jun 30, 2020 | 20.21 Mn |
| Mar 31, 2020 | 18.20 Mn |
| Dec 31, 2019 | 24.75 Mn |
| Sep 30, 2019 | 18.71 Mn |
| Jun 30, 2019 | 14.95 Mn |
| Mar 31, 2019 | 9.90 Mn |
| Dec 31, 2018 | 9.67 Mn |
| Sep 30, 2018 | 3.63 Mn |
| Jun 30, 2018 | 3.23 Mn |
| Mar 31, 2018 | 2.88 Mn |
| Dec 31, 2017 | 4.42 Mn |
| Sep 30, 2017 | 2.90 Mn |
| Jun 30, 2017 | 2.01 Mn |
| Mar 31, 2017 | 2.60 Mn |
| Dec 31, 2016 | 2.40 Mn |
| Sep 30, 2016 | 2.41 Mn |
| Jun 30, 2016 | 2.62 Mn |
| Mar 31, 2016 | 3.13 Mn |
| Dec 31, 2015 | 4.63 Mn |
| Sep 30, 2015 | 3.91 Mn |
| Jun 30, 2015 | 5.54 Mn |
| Mar 31, 2015 | 9.43 Mn |
| Dec 31, 2014 | 8.67 Mn |
| Sep 30, 2014 | 9.22 Mn |
| Jun 30, 2014 | 4.74 Mn |
| Mar 31, 2014 | 4.59 Mn |
| Dec 31, 2013 | 3.98 Mn |
| Sep 30, 2013 | 6.58 Mn |
| Jun 30, 2013 | 2.70 Mn |
| Dec 31, 2012 | 2.17 Mn |
| Mar 31, 2012 | 2.27 Mn |
| Dec 31, 2011 | 2.49 Mn |
| Sep 30, 2011 | 422,654.00 |
| Jun 30, 2011 | 656,136.00 |
| Dec 31, 2010 | 313,709.00 |